Twitter
Advertisement

Cipla gets CCI nod to sell 26% in consumer healthcare business

In November last year, the company signed an agreement to sell 26.11% in Cipla Health to FIL Capital Investments (Mauritius) II Limited.

Latest News
article-main
FacebookTwitterWhatsappLinkedin

Drug major Cipla has received approval from fair trade regulator CCI to sell about 26$ stake in its consumer healthcare business to Mauritius-based FIL Capital Investments.

In November last year, the company signed an agreement to sell 26.11% in Cipla Health to FIL Capital Investments (Mauritius) II Limited.

However, the financial details of the deal were not disclosed.

In a tweet on Thursday, the Competition Commission of India (CCI) said that it "approves acquisition of 26.11% stake in Cipla Health Ltd by FIL Capital Investments (Mauritius) II Ltd".

Through the consumer healthcare business, Cipla has entered the over-the-counter (OTC) healthcare market in India.

In July last year, Cipla's board had approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II or its affiliates in the consumer healthcare business.

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement